1. Home
  2. BLTE vs CHE Comparison

BLTE vs CHE Comparison

Compare BLTE & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$137.18

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

CHE

Chemed Corp

HOLD

Current Price

$439.17

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLTE
CHE
Founded
2018
1970
Country
United States
United States
Employees
N/A
15811
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
5.8B
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
BLTE
CHE
Price
$137.18
$439.17
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
$198.00
$501.50
AVG Volume (30 Days)
104.2K
223.3K
Earning Date
05-08-2026
04-23-2026
Dividend Yield
N/A
0.57%
EPS Growth
N/A
N/A
EPS
N/A
4.84
Revenue
N/A
$2,529,978,000.00
Revenue This Year
N/A
$6.56
Revenue Next Year
$492.11
$6.23
P/E Ratio
N/A
$90.82
Revenue Growth
N/A
4.06
52 Week Low
$56.68
$365.21
52 Week High
$200.00
$580.50

Technical Indicators

Market Signals
Indicator
BLTE
CHE
Relative Strength Index (RSI) 31.51 65.49
Support Level $103.94 $423.89
Resistance Level $172.02 $457.32
Average True Range (ATR) 7.11 11.19
MACD -1.16 0.74
Stochastic Oscillator 7.06 78.41

Price Performance

Historical Comparison
BLTE
CHE

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About CHE Chemed Corp

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Share on Social Networks: